Two Grants Totaling EUR 1.65 Million by the German Federal Ministry of Education and Research (BMBF) to Support Apogenix´ Research
9/22/2008 3:30:05 PM
HEIDELBERG, Germany, Sept. 19, 2008 - Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced the granting of additional research funding amounting to EUR 1.65 million. The two grants were awarded by the German Federal Ministry of Education and Research (BMBF) in the context of Germany´s renowned programs “BioChancePlus” and “Innovative Molecular and Cellular-Based Therapies”.
comments powered by